Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MTPC, Anaphore Agree to Jointly Develop Drugs for Autoimmune Diseases
January 3, 2011
- Nippon Kayaku to Lead Antibody Biosimilar Market in Japan: Nomura Securities Report
January 3, 2011
- Eisai Applies for Marketing Authorization for Embolic Beads
January 3, 2011
- Sanofi-aventis to Tie Up with Merck Serono in Oncology
January 3, 2011
- Taiyo Holds Meetings with Clients on GMP Compliance Measures
January 3, 2011
- ARBs Effective for Improving Albuminuria: DSP survey
January 3, 2011
- DSP Completes Merger of Chinese Subsidiaries
January 3, 2011
- US Generics Market to Outgrow New Drugs Market: IGPA Annual Conference
January 3, 2011
- Pfizer Applies for Solu-Medrol Based on Data from the Public Domain
January 3, 2011
- Shionogi, Wakamoto to Copromote Non-prescription Oral Care Products
January 3, 2011
- Apollo Medical to Expand Overseas Training Program for Its Employees
January 3, 2011
- FDA Recommends Withdrawal of Approval for Breast Cancer for Avastin
January 3, 2011
- EPS Acquires SMO in Taiwan
January 3, 2011
- Prospects for Simultaneous Global Development: 1 (1)
January 3, 2011
- Eisai, Elan Settle Zonegran Off-Label Promotion Disputes
January 3, 2011
- Prospects for Simultaneous Global Development: 1 (2)
January 3, 2011
- M3 to Expand Its e-Detailing Services in Oncology
January 3, 2011
- Seikagaku to File NDA for SI-6603 in Mid 2011
January 3, 2011
- PSJ to Raise Public Awareness of Drugs
January 3, 2011
- Ono Obtains Positive PIIb Results for Carfilzomib
January 3, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…